Cosmos Health Targets $22.7M Revenue and $17M Profit in U.S. Nutraceutical Launch
COSM•Cosmos Health’s U.S. 18 Series nutraceutical platform projects over $22.7M in annualized revenue and $17.0M in gross profit from four products, implying ~75% gross margins. The company reports early customer demand since launch and plans to expand direct-to-consumer sales into additional retail channels.
1. U.S. 18 Series Product Projections
Cosmos Health introduced four 18 Series nutraceuticals—Noor18™, Liv18™, Fort18™ and Cur18™—with combined projected annualized U.S. revenue exceeding $22.7 million and implied gross profit of approximately $17.0 million based on a ~75% margin.
2. Early Demand and Margin Guidance
Since launching the 18 Series, the company has observed encouraging early consumer traction across its platform, supporting its margin guidance of about 75% gross profit on new product sales to drive profitability.
3. Expansion Plans and Long-Term Outlook
Cosmos Health plans to scale its direct-to-consumer model into additional retail channels, target a total portfolio of 18 science-driven products, and leverage further U.S. projects to enhance long-term revenue and cash generation.
